Position paper - Guidelines for the prevention and treatment of atherosclerosis and cardiovascular diseases: Treatment of diabetes mellitus, dyslipidemia and the prevention of stroke

Harefuah

Volumn 144, Issue 9, 2005, Pages 647-654

  Bitzur, Rafael ^a   Harats, Dror ^a   Rubinstein, Ardon ^b  

^a SHEBA MEDICAL CENTER   (Israel)

^b TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

Author keywords

Atherosclerosis; Diabetes mellitus; Dyslipidemia; Ischemic heart disease; Stroke

Indexed keywords

ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; DIABETES MELLITUS; DYSLIPIDEMIA; ISCHEMIC HEART DISEASE; PRACTICE GUIDELINE; REVIEW; STROKE; ARTERIOSCLEROSIS; ARTICLE; CEREBROVASCULAR ACCIDENT; HUMAN; HYPERLIPIDEMIA;

ARTERIOSCLEROSIS; CARDIOVASCULAR DISEASES; CEREBROVASCULAR ACCIDENT; DIABETES COMPLICATIONS; DIABETES MELLITUS; HUMANS; HYPERLIPIDEMIAS; PRACTICE GUIDELINES;

EID: 27744474490     PISSN: 00177768     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (32)

1. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular complications in type 2 diabetes: UKPDS 38. BMJ, 1998; 317: 703-713
2. UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes: UKPDS 33. Lancet, 1998; 352: 837-53
3. Colhoun HM, Betteridge DJ, Durrington PN & al, Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet, 2004; 364: 685-96.
4. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebo-controlled trial. Lancet, 2002; 360: 7-22.
5. UK Prospective Diabetes Study Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes: UKPDS 34. Lancet, 1998; 352: 854-65.
6. Grundy SM, Cleeman JI, Bairey Merz CN & al, Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. Circulation, 2004; 110: 227-239.
7. De Backer G, Ambrosioni E, Borch-Johnsen K & al, European guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J, 2003; 24: 1601-1610.
8. Cannon CP, Braunwald E, McCabe CH & al, Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med, 2004; 350: 1495-1504.
9. Nissen SE, Tuzcu EM, Schoenhagen P & al, Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA, 2004; 291: 1071-1080.
10. LaRosa JC, Grundy SM, Waters DD & al, Intensive lipid lowering with Atorvastatin in patients with stable coronary disease. N Engl J Med, Published at www.nejm.org March 8, 2005 (10.1056/NEJMoa050461).
11. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA, 2001; 285: 2486-2497.
12. Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet, 1994; 344: 1383-89.
13. Shepherd J, Cobbe SM, Ford I & al, Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med, 1995; 333: 1301-1307.
14. Sacks FM, Pfeffer MA, Moye LA & al, The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med, 1996; 335: 1001-1009.
15. The Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med, 1998; 339: 1349-1357.
16. Post coronary artery bypass graft trial investigators. The effect of aggressive lowering of low-density lipoprotein cholesterol level and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts. N Engl J Med, 1997; 336: 153-162.
17. Fruchart JC, Brewer HB & Leitersdorf E, Consensus for the use of fibrates in the treatment of dyslipoproteinemia and coronary heart disease. Am J Cardiol, 1998; 81: 912-917.
18. Rubins HB, Robins SJ, Collins D & al, Gemfibrozil for the Secondary Prvention of Coronary Heart Disease in Men With Low Levels of High-Density Lipoprotein Cholesterol. N Engl J Med, 1999; 341: 410-418.
19. Xydakis AM & Ballantyne CM, Combination Therapy for Combined Dyslipidemia. Am J Cardiol, 2002; 90 (suppl): 21K-29K.
20. Schwartz GG, Olsson AG, Ezekowitz MD & al, Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA, 2001; 285: 1711-1718.
21. U.S. Preventive Services Task Force Aspirin for the Primary Prevention of Cardiovascular Events: Recommendation and rationale. Ann Intern Med, 2002; 136: 157-160.
22. Smith SC, Blair SN, Bonow RO & al, AHA/ACC Guidelines for Preventing Heart Attack and Death in Patients with Atherosclerotic Cardiovascular Disease: 2001 Update. Circulation, 2001; 104: 1577-1579.
23. Lewis EJ, Hunsicker LG, Clarke WR & al, Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med, 2001; 345: 851-860.
24. The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an Angiotensin-Converting-Enzyme Inhibitor, Ramipril, on Cardiovascular Events in High-Risk Patients. N Engl J Med, 2000; 342: 1385-1391.
25. Coull BM, Williams LS, Goldstein LB & al, Anticoagulants and antiplatelet agents in acute ischemic stroke report of the Joint Stroke Guideline Development Committee of the American Academy of Neurology and the American Stroke Association (a Division of the American Heart Association). Stroke, 2002; 33: 1934-1942.
26. Barnett HJM, Taylor DW, Eliasziw M & al, Benefit of carotid endarterectomy in patients with symptomatic moderate or severes Stenosis. N Engl J Med, 1998; 339: 1415-1425.
27. Elaine M, Hylek EM, Go AS & al, Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation. N Engl J Med, 2003; 349: 1019-1026.
28. Thune I, Brenn T, Lund E & Gaard M, Physical activity and the risk of breast cancer. N Engl J Med, 1997; 336: 1269-1275.
29. Ridker PM, Buring JE, Cook NR & Rifai N, C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-Year follow-up of 14 719 initially healthy american women. Circulation, 2003; 107: 391-397.
30. Pearson TA, Mensah GA, Alexander RW & al, Markers of inflammation and cardiovascular disease application to clinical and public health practice. A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation, 2003; 107: 499-511.